Special Issue on “Pleiotropic Benefits of Melatonin: From Basic Mechanisms to Disease”

Potes, Yaiza; Caballero, Beatriz

doi:10.3390/ijms24065223

Cited by 2 publications

(2 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…While this protective effect has been shown to be primarily receptor-mediated, 77 it could also be attributed to its pleiotropic effects on ER-stress signaling pathways. 74,75,80 For example, melatonin has been shown to preserve intestinal barrier function and restore SIRT1 and SIRT3 activity/protein expression in the small intestine of sepsis models. 81 Xu et al have shown that melatonin enhances NF-κB deacetylation, thereby reducing the inflammatory response, and oxidative stress.…”

Section: Targeting Er-stress In Mucositismentioning

confidence: 99%

“…Interestingly, melatonin has been indicated to protect against surfactant‐induced, 76,77 and ethanol‐induced 78,79 increases in small intestinal mucosal permeability in rats, highlighting its potential as a treatment for a compromised intestinal mucosal barrier. While this protective effect has been shown to be primarily receptor‐mediated, 77 it could also be attributed to its pleiotropic effects on ER‐stress signaling pathways 74,75,80 . For example, melatonin has been shown to preserve intestinal barrier function and restore SIRT1 and SIRT3 activity/protein expression in the small intestine of sepsis models 81 .…”

Section: Therapeutic Strategies Targeting Er‐stress In Mucositismentioning

confidence: 99%

See 1 more Smart Citation

Endoplasmic reticulum stress in the pathogenesis of chemotherapy‐induced mucositis: Physiological mechanisms and therapeutic implications

Heindryckx,

Sjöblom

2024

Acta Physiologica

View full text Add to dashboard Cite

Chemotherapy is a common and effective treatment for cancer, but these drugs are also associated with significant side effects affecting patients' well‐being. One such debilitating side effect is mucositis, characterized by inflammation, ulcerations, and altered physiological functions of the gastrointestinal (GI) tract's mucosal lining. Understanding the mechanisms of chemotherapy‐induced intestinal mucositis (CIM) is crucial for developing effective preventive measures and supportive care. Chemotherapeutics not only target cancer cells but also rapidly dividing cells in the GI tract. These drugs disrupt endoplasmic reticulum (ER) homeostasis, leading to ER‐stress and activation of the unfolded protein response (UPR) in various intestinal epithelial cell types. The UPR triggers signaling pathways that exacerbate tissue inflammation and damage, influence the differentiation and fate of intestinal epithelial cells, and compromise the integrity of the intestinal mucosal barrier. These factors contribute significantly to mucositis development and progression. In this review, we aim to give an in‐depth overview of the role of ER‐stress in mucositis and its impact on GI function. This will provide valuable insights into the underlying mechanisms and highlighting potential therapeutic interventions that could improve treatment‐outcomes and the quality of life of cancer patients.

show abstract

Section: Targeting Er-stress In Mucositismentioning

confidence: 99%

Section: Therapeutic Strategies Targeting Er‐stress In Mucositismentioning

confidence: 99%

Endoplasmic reticulum stress in the pathogenesis of chemotherapy‐induced mucositis: Physiological mechanisms and therapeutic implications

Heindryckx,

Sjöblom

2024

Acta Physiologica

View full text Add to dashboard Cite

show abstract

Investigation of melatonin effect on the outcome of moderate and severe diffuse axonal injury (DAI) - A randomized, placebo-controlled clinical trial

Ghaedamini,

Karamoozian,

Hadad

et al. 2024

Preprint

View full text Add to dashboard Cite

Objective The efficacy of melatonin in improving diffuse axonal injury has not been evaluated. This study investigated the melatonin effect on moderate and severe diffuse axonal injury outcomes. Methods This was a randomized clinical trial. The case group (N = 35) received 3mg of oral melatonin, and the control group (N = 35) received Placebo. extended-Glasgow Outcome Scale (e-GOS) and Functional Independence Measure (FIM) scores at baseline, 1 month, 3 months, and 6 months after injury were defined as primary outcomes, and Glasgow Coma Scale (GCS) at baseline, 24 hours, 48 hours, 1 week, 2week until discharge defined as secondary outcomes. Results A total of 70 patients were enrolled and were randomly allocated into the intervention (n = 35) and placebo (n = 35) groups. The results showed that there was no statistically significant difference between melatonin and placebo in GOS (P > 0.05) and FIM (P > 0.05) at 3 months and 6 months after hospitalization but the mean E-GOS (P = 0.001) and FIM (P = 0.001) at the first month was significantly higher in the melatonin group. Conclusions The use of melatonin as a low-cost and safe medicine complementary treatment in people with DAI can accelerates functional recovery.

show abstract

Special Issue on “Pleiotropic Benefits of Melatonin: From Basic Mechanisms to Disease”

Abstract: Melatonin (N-acetyl-5-methoxytryptamine) is a multifunctional hormone that is naturally produced from tryptophan and released rhythmically throughout the night by the pineal gland to regulate sleep–wake cycles [...]

Cited by 2 publications

References 20 publications

Endoplasmic reticulum stress in the pathogenesis of chemotherapy‐induced mucositis: Physiological mechanisms and therapeutic implications

Endoplasmic reticulum stress in the pathogenesis of chemotherapy‐induced mucositis: Physiological mechanisms and therapeutic implications

Investigation of melatonin effect on the outcome of moderate and severe diffuse axonal injury (DAI) - A randomized, placebo-controlled clinical trial

Contact Info

Product

Resources

About